DK2464645T3 - Kondenserede, heterocykliske forbindelser som jernkanalmodulatorer - Google Patents

Kondenserede, heterocykliske forbindelser som jernkanalmodulatorer Download PDF

Info

Publication number
DK2464645T3
DK2464645T3 DK10737724.4T DK10737724T DK2464645T3 DK 2464645 T3 DK2464645 T3 DK 2464645T3 DK 10737724 T DK10737724 T DK 10737724T DK 2464645 T3 DK2464645 T3 DK 2464645T3
Authority
DK
Denmark
Prior art keywords
phenyl
pyridine
trifluoromethoxy
triazolo
methyl
Prior art date
Application number
DK10737724.4T
Other languages
English (en)
Inventor
Britton Corkey
Elfatih Elzein
Rao Kalla
Tetsuya Kobayashi
Dmitry Koltun
Xiaofen Li
Eric Parkhill
Thao Perry
Robert Jiang
Gregory Notte
Jeff Zablocki
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK2464645T3 publication Critical patent/DK2464645T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pyridine Compounds (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (14)

  1. KONDENSEREDE, HETEROCYKLISKE FORBINDELSER SOM JERNKAN ALMODULATORER
    1. Forbindelse med formlen III:
    hvor: R1 er en aryl eller heteroaryl udvalgt fra gruppen bestående af:
    hvor arylen eller heteroraylen er substitueret med én, to eller tre substituenter, der er uafhængigt udvalgt blandt gruppen bestående af hydroxyl, halo, -N02, CN, -SF5, -Si(CH3)3 -0-CF3, -O-R20, -S-R20, -C(0)-R20, C(0)0H, -N(R20)(R22), -C(O)-N(R20)(R22), -N(R20)-C(O)-R22, -N(R20)-S(=O)2-R26, -S(=0)2-R20, -S(=O)2-N(R20)(R22), CrC3-alkoxy, C1.4-alkyl, C2.4-alkenyl, C2.4-alkynyl, cycloalkyl, heteroaryl og heterocyclyl; hvor alkoxy, alkyl, alkenyl, alkynyl, heteroaryl, cycloalkyl, eller heterocyclyl eventuelt er substitueret med én, to eller tre substituenter, der er uafhængigt udvalgt blandt hydroxyl, halo, -N02, -O- CF3, -0-CHF2, phenyl, heterocyclyl, heteroaryl, cycloalkyl, -N(R20)(R22), -C(0)-R20, -C(0)-0-R20, -C(O)-N(R20)(R22), -CN og -O-R20, eller hvor R1 er substitueret med én, to eller tre substituenter, der er uafhængigt udvalgt blandt
    R2 er uafhængigt udvalgt fra gruppen bestående af hydrogen, eventuelt substitueret alkyl, amino, eventuelt substitueret alkoxy, -CF3, -0-CF3, -CN og -N(R20)C(O)-R22; R3 er uafhængigt udvalgt fra gruppen bestående af hydrogen, alkyl, -CF3, -halo og -O-R24; R4 er uafhængigt udvalgt fra gruppen bestående af hydrogen, hydroxyl, halo, C^-alkyl, CrC3-alkoxy, -R25-N(R20)(R22), -R^-O-R20, -R25-C(0)-0-R20, -R25-C(O)-N(R20)(R22), -R25-C(O)-O-N(R20)(R22), -R25-N(R20)-C(O)-R22 og -R25-O-C(O)-N(R20)(R22), hvor alkyl eventuelt er substitueret med én, to eller tre substituenter, der er uafhængigt udvalgt blandt hydroxyl og halo, Q er udvalgt fra en kovalent binding eller C2.4-alkynylen; Ra er hydrogen, C^-alkyl, Cw-alkoxy, -C(0)-0-R26, -C(0)-N(R26)(R28), -N(R20)-S(=O)2-R20, cycloalkyl, aryl, heteroaryl og heterocyclyl, hvor alkyl eventuelt er substitueret med én, to eller tre substituenter, der er uafhængigt udvalgt blandt hydroxyl, halo, -N02, -0-CF3, -0-CHF2, cycloalkyl, -CN og C^-alkoxy; og alkoxy, cycloalkyl, aryl, heterocyclyl eller heteroaryl eventuelt er substitueret med én, to eller tre substituenter, der er uafhængigt udvalgt blandt hydroxyl, halo, -N02, -0-CF3, -0-CHF2, phenyl, heterocyclyl, heteroaryl, cycloalkyl, -N(R20)(R22), -C(0)-R20, -C(0)-0-R20, -C(O)-N(R20)(R22), -CN og -O-R20; eller Ra er -Y-Z-R25-R23-R20, hvor, Y er en kovalent binding eller udvalgt fra CrC3-alkylen eventuelt substitueret med én eller to Cr C3-alkyl- eller fluorgrupper; Z er C2.4-alkynylen, -O-, -S-, -NR", -NR5'-C(0)-, -NR"-C(0)-NR5'- eller -CiO)-NR3-, hvor hvert R" og R5 uafhængigt er hydrogen eller lavere Ci_6-alkyl; og endvidere hvor alkyl eventuelt er substitueret med én, to eller tre substituenter, der er uafhængigt udvalgt blandt hydroxyl, halo, -N02, -O-CF3, -0-CHF2, phenyl, heterocyclyl, heteroaryl, cycloalkyl, -N(R20)(R22), -C(0)-R20, -C(0)-0-R20, -C(O)-N(R20)(R22), -CN og -O-R20, eller hvor Ra er udvalgt fra gruppen bestående af
    R20 og R22 er i hvert tilfælde uafhængigt udvalgt fra gruppen bestående af hydrogen, Ci-Ci5-alkyl, C2-Ci5-alkenyl, C2-C15-alkynyl, cycloalkyl, heterocyclyl, aryl og heteroaryl, hvor alkyl, alkenyl, alkynyl, heterocyclyl, aryl og heteroaryl eventuelt er substitueret med én, to eller tre substituenter, der er uafhængigt udvalgt blandt hydroxyl, halo, alkyl, mono- eller dialkylamino, alkyl eller aryl eller heteroarylamid, -N02, -S02R26, -CN, C^-alkoxy, -CF3, -OCF3, aryl, cycloalkyl og heteroaryl; eller når R20 og R22 er bundet til et fælles nitrogenatom, kan R20 og R22 forenes for at danne en heterocyklisk ring, der derefter eventuelt substitueres med én, to eller tre substituenter, der er uafhængigt udvalgt blandt hydroxyl, halo, alkyl, mono- eller dialkylamino, alkyl- eller aryl- eller heteroarylamid, -N02, -S02R26, -CN, C1.3-alkoxy, -CF3 og -OCF3, aryl og cycloalkyl; R23 er en kovalent binding eller er udvalgt fra gruppen bestående af cycloalkylen, heterocyclylen, arylen og heteroarylen, hvor cycloalkylen, heterocyclylen, arylen og heteroarylen eventuelt er substitueret med én til tre substituenter, der er uafhængigt udvalgt blandt hydroxyl, halo, alkyl, mono- eller dialkylamino, alkyl eller aryl eller heteroarylamid, -N02, -S02R26, -CN, C^-alkoxy, - CF3, -OCF3, aryl, cycloalkyl og heteroaryl; R24 er i hvert tilfælde uafhængigt udvalgt fra alkyl eller aryl, der hver især eventuelt kan substitueres med 1, 2, eller 3 grupper uafhængigt udvalgt fra hydroxyl, -OCF3, halo, Ci-C3-alkoxy, -O-R20 eller alkyl eventuelt substitueret med halo, -N02, -CF3, -0-CF3, -N(R20)(R22), -C(0)-R20, -C(0)-0-R20, -C(O)-N(R20)(R22), -CN eller -O-R20; R25 er i hvert tilfælde uafhængigt en kovalent binding eller udvalgt fra Ci-C3-alkylen eventuelt substitueret med én eller to CrC3 alkylgrupper; og R26 og R28 er i hvert tilfælde uafhængigt udvalgt fra hydrogen, alkyl, eller cycloalkyl, hvor alkyl og cycloalkyl endvidere kan være substitueret med fra 1 til 3 substituenter, der er uafhængigt udvalgt blandt hydroxyl, halo, C1.4-alkoxy, -CF3 og -OCF3; eller et farmaceutisk acceptabelt salt, en farmaceutisk acceptabel ester eller et farmaceutisk acceptabelt solvat deraf, forudsat at a. når Ra er -Y-Z-R25-R23-R20, Y ikke er en kovalent binding og Z er -O-, -S-, -C(0)-NR3-, -NR5 -C(O)- eller NR"-, så kan R25 ikke være en binding; b. når Ra er -Y-Z-R25-R23-R20, Y er en kovalent binding og Z er -O-, -S- eller NR"-, så er R25 en kovalent binding og R23 er ikke cycloalkylen; c. når Z er -NRa-C(0)-, så er Y ikke en kovalent binding; d. R23 og R25 kan ikke begge være kovalente bindinger; og e. når Q er en binding, og R1 er heteroaryl, så kan R1 heteroaryl ikke være yderligere substitueret med phenyl og f. når R2 er substitueret alkyl, så er Ra ikke alkyl, cycloalkyl eller heterocyclyl.
  2. 2. Forbindelse ifølge krav 1, hvor Q er C2.4-alkynylen.
  3. 3. Forbindelse ifølge krav 2, der er udvalgt fra gruppen bestående af: 3-(trifluormethyl)-6-{[4-(trifluormethyl)phenyl]ethynyl}[l,2,4]triazol[4,3-a]pyridin; 2,2-difluor-2-(6-{[4-(trifluormethyl)phenyl]ethynyl}[l,2,4]triazol[4,3-a]pyridin-3-yl)ethanol; 3-( 1, l-difluor-2-methoxyethyl)-6- {[4-(trifluormethyl)phenyl]ethynyl} [ 1,2,4] triazol[4,3-a]pyridin; 3-phenoxy-6- {[4-(trifluormethyl)phenyl]ethynyl j [ 1,2,4] triazol[4,3-a]pyridin; 3-(l,l-difhior-2-methoxyethyl)-6-{[4-(trifluormethoxy)phenyl]ethynyl}[l,2,4]triazol[4,3-a]pyridm og 3-(l,l-difluor-2-methoxyethyl)-6-[(4-fluorphenyl)ethynyl][l,2,4]triazol[4,3-a]pyridin.
  4. 4. Forbindelse ifølge krav 1, hvor R1 er heteroaryl.
  5. 5. Forbindelse ifølge krav 4, der er udvalgt fra gruppen bestående af: 6-(6-cyclopropylpyridin-3-yl)-3-(trifluormethyl)[l,2,4Jtriazol[4,3-a]pyridin; 6-(2-cyclopropylpyrimidin-5-yl)-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 3-(trifluormethyl)-6-[6-(trifluormethyl)pyridin-3-yl][l ,2,4]triazol[4,3-a]pyridin; 6-[6-(2,2,2-trifluorethoxy)pyridin-3-yl]-3-(trifluonnetliyl)[l,2,4]tiiazol[4,3-a]pyridin; 6-(5-cyclopropyl-l,3,4-thiadiazol-2-yl)-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 3-(trifluormethyl)-6-[6-(trifluormethyl)pyxidazin-3-yl] [ 1,2,4] triazol[4,3-a]pyridin; 3-(trifluormethyl)-6-[2-(trifluormethyl)pyTimidin-5-yl][l,2,4]triazol[4,3-a]pyridin; 3-(l,l-difluor-2-methoxyethyl)-6-[6-(2,2,2-trifluorethoxy)pyridin-3-yl][l,2,4]triazol[4,3-a]pyridin; 6-[6-(cyclopropyloxy)pyridin-3-yl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[6-(2,2,2-trifluorethoxy)pyridazm-3-yl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridm; 3-[(cyclopropylmethoxy)(ditluor)methyl]-6-[6-(trifluormethyl)pyridin-3-yl][l,2,4]triazol[4,3- a]pyridin; 3-{difluor[(5-phenyl-l,2-oxazol-3-yl)methoxy]methyl]-6-[6-(trifluormethyl)pyridin-3-yl][l,2,4]triazol[4,3-a]pyridin og 3-{difluor[(5-phenyl-l,2-oxazol-3-yl)methoxy]methyl]-6-[6-(2,2,2-trifluorethoxy)pyridin-3- yl][l,2,4]triazol[4,3-a]pyridin.
  6. 6. Forbindelse ifølge krav 1, hvor Ra er (i) aryl, (ii) -Y-Z-R25-Ra3-R20, hvor fortrinsvis Y er -CF2- og Z er O; eller (iii) alkyl eventuelt substitueret med halo, hydroxyl, cyclopropyl, methoxy eller amino.
  7. 7. Forbindelse ifølge krav 6, der er udvalgt fra gruppen bestående af: (i) 3-phenyl-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3- phenyl-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-8-amin; 3,6-bis[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm; 4- {6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}benzensulfonamid; N-(4-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}phenyl)methansulfonamid; 4- {6- [4-(trifluormethoxy)phenyl] [1,2,4] triazol[4,3-a]pyridin-3- yl} benzamid; diethyl 3,3'-[l,2,4]triazol[4,3-a]pyridin-3,6-diyldibenzoat; ethyl 4-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}benzoat; ethyl 3-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}benzoat; N-(2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}phenyl)methansulfonamid; N-methyl-3-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl]benzamid og N-[5-(frifluormethoxy)-2-{3-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4.3-a]pyridin-6-yl Jphenyl] acetamid; (ii) 3-[difluor(methoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazolo [4,3-a]pyridin; 3-[di£luor(2-methoxyethoxy)methyl]-6-[4-(trifluormethoxy)phenyl] [ 1,2,4] triazol[4,3-a]pyridin; 3-{difluor[(3-methyloxetan-3-yl)methoxy]methyl}-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm; 3-{difluor[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy] methyl }-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm; 3-[(benzyloxy)(difluor)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[difluor(pyTidin-4-ylmethoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 2- (dif]uor{6-[4-(trif]uormethoxy)phenyl][1,2,4]triazol[4,3-a]pyridin-3-yl}methoxy)ethanol; l-(difluor{6-[4-(lrifluormelhoxy)phenyl][l,2,4]lriazol[4,3-a]pyridin-3-yl}melhoxy)propan-2-ol; 3- {difluor[(5-methyl-l,2-oxazol-3-yl)methoxy]methyl}-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[difluor(pyTidin-3-ylmethoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{[(5-cyclopropyl-l,2,4-oxadiazol-3-yl)melhoxy](diriuor)methyl}-6-[4- (trifluormethoxy)phenylJ[l,2,4Jtriazol[4,3-aJpyxidin; 3-(difluor{[5-(2-methylpropyl)-l,2,4-oxadiazol-3-yl]methoxy}methyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyxidin; 3-(difluor{[5-(propan-2-yl)-l,2,4-oxadiazol-3-yl]methoxy}methyl)-6-[4- (triiluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3- [difluor(pyTidin-2-ylmethoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 4- [(difluor{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl} methoxy)methyl] quinolin; 3-[(cyclopiOpylmethoxy)(difluor)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]tnazol[4,3- ajpyridin; 3 - {difluor[ (1 -phenyl-1 Η-1,2,3 -triazol-4- yl)methoxy] methyl }-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyxidin; 3-[difluor(pyridazin-3-ylmethoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-{difluor[l-(4-fluorphenyl)ethoxy]methyl}-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-{dif]uor[(1-methyl-5-phenyl-1H-pyTazol-3-yl)methoxy]methyl}-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm; 3-{[(2,2-difluor-l,3-benzodioxol-5-yl)methoxyJ(difluor)methyl}-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyxidin; 3-{[(2,5-dimethyl-l,3-oxazol-4-yl)methoxy](difluor)methyl}-6-[4-(trif]uormethoxy)phenyl][1,2,4]triazolo [4,3-a]pyridin; 3- {difluor[ (5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy] methyl J -6- [4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{difhior[l-(pyridin-2-yl)ethoxy]methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-|[l-(4-chlorphenyl)ethoxy](difluor)methyl}-6-[4-(trilluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-[difluor(pyrimidm-2-ylmethoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-{[l-(2,4-dichlorphenyl)ethoxy](difluor)methyl}-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; l-[(difluor{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm-3-yl} methoxy)methyl] c yclobutanol; tert-butyl (2S)-2-[(difhior(6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3- yl} methoxy)methyl] pyrrolidine-1 -carboxylat; 3-{[(5-cyclobutyl-l,2,4-oxadiazol-3-yl)methoxy](difluor)methyl}-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[(difhior{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl) methoxy)methyl] benzonitril; 3-(ditluor{3-[(2-methoxyphenyl)sulfanyl]-2-methylpropoxy}methyl)-6-[4-(trifluormethoxy)phenyl][ 1,2,4] triazolo [4,3-a]pyridin; 3-[difluor(l-{3-[4-(trifluormethyl)phenyl]-l,2-oxazol-5-yl]ethoxy)methyl]-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(difluor{2-[4-(4-methoxyphenyl)piperazin-l-yl]ethoxy}methyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm; 3-{[(3-cyclopropyl-l-methyl-lH-pyrazol-5-yl)methoxy](difluor)methyl}-6-[4- (trifluormethoxy)phenyll[l,2,41triazol[4,3-alpyridin; 5-[(difluor(6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm-3-yl} methoxy)methyl] quinolin; 3-[ l-(difluor{ 6-[4-(trifluormethoxy)phenyl] [ l,2,4]triazol[4,3-a]pyridin-3-yl} methoxy)ethyl] quinolin; 3- {[2-(2,6-dimethylphenoxy)ethoxy] (difluor) methyl} - 6- [4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3 -} dilluorf (1 -phenyl-1 H-pyrazol-4-yl)methoxy] methyl }-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3- [difluor({2-[4-(trifluormethyl)phenyl]-l,3-oxazol-4-yl]methoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 4- [(difluor{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}methoxy)methyl]-2-methylquinoline; 4-[(difluor{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm-3-yl}methoxy)methyl]-2- (trifluormethyl)qmnolin; 6-[(difliior{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl) methoxy)methyl] quinoxalin; 3-[(but-2-yn-l-yloxy)(difluor)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3 - {[ (2,2- difluorcyclopropyl)methoxy] (difluor) methyl } - 6- [4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(difluor[(3-phenylprop-2-yn-l-yl)oxy]methyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-{difluor[(l-methyl-lH-benzimidazol-2-yljmethoxy] methyl }-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{[(l-benzyl-lH-l,2,3-triazol-4-yl)methoxy](difluor)methyl}-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3a]pyridin; 3-|difluor[(5-phenyl-l,2-oxazol-3-yl)methoxy]methyl}-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3- {difluor[ (2-phenyl-1,3-oxazol-4-yl)methoxy] methyl} -6- [4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{difluor[(5-methyl-2-phenyl-2H-l,2,3-triazol-4-yl)methoxy]methyl}-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{difluor[(l-methyl-lH-pyrazol-3-yl)methoxy]methyl}-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[ ([l-(4-chlorphenyl)-5-methyl-lH-pyrazol-3-yl]methoxy) (difluor)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[(3,3-diphenylpropoxy)(difluor)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-(difluor{[3-(pyrimidin-2-yl)benzyl]oxy}methyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-(difluor{[3-(pyridin-3-yl)benzyl]oxy}methyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3- {difluor[ (1-methyl-1 H-indazol-3-yl)methoxy] methyl} -6- [4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(difluor{[2-(lH-l,2,4-triazol-l-yl)benzyl]oxy}methyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(difluor{[2-(2-methyl-lH-imidazol-l-yl)benzyl]oxy}methyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(difluor([2-phenyl-5-(trifluormethyl)-l,3-oxazol-4-yl]methoxy)methyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(difluor{[l-phenyl-3-(trifluormethyl)-lH-pyrazol-4-yl]methoxy}methyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyTidin; 3-(difluor{[6-(lH-p}Tazol-l-yl)pyridin-3-yl]methoxy}methyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm; 6-cyclopropyl-2'-[(difluor{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3- yl}methoxy)methyl]-3,4'-bipyridin; 3-[{[3-(4-cyclopropyl-lH-imidazol-l-yl)benzyl]oxy}(difluor)methyl]-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(difluor{[5-(4-fluorphenyl)-l,2-oxazol-3-yl]methoxy}methyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyTidin; 3 -(difluor {[2- (piperidin-1 - yl)pyridin-4- yl] methoxy } methyl)- 6- [4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-([(2,2-dimethyl-2,3-dihydro-l-benzofuran-7-yl)methoxy](difluor)methyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{[2-(2,6-difluorphenyl)ethoxy](difluor)methylJ-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-{difluor[(5-phenyl-l,2,4-oxadiazol-3-yl)methoxy]methyl}-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm; 3-[{[2-(6-cyclopropylpyridin-3-yl)benzyl]oxyJ(difluor)methyl]-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[{[5-(2-chlorphenyl)-l,2-oxazol-3-yl]methoxyl(difluor)methyl]-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(difluor{[2-(pyridin-3-yl)benzyl]oxy}methyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-(difluor{[2-(lH-pyrazol-l-yl)benzyl]oxy}methyl)-6-[4- (trifluormethoxy)phenyllil,2,41triazoli4,3-alpyridin; 3-(l,l-difluor-2-methoxyethyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 2,2-difluor-2-[6-(4-phenoxyphenyl)[l,2,4]triazol[4,3-a]pyridin-3-yl]ethanol; 3-(l,l-difluor-2-methoxyethyl)-6-(4-phenoxyphenyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(4-chlorphenoxy)phenyl]-3-(l,l-difluor-2-methoxyethyl)[l ,2,4]triazol[4,3-a]pyridin; 3-(l,l-difluor-2-melhoxyethyl)-6-[4-(4-fluorphenoxy)phenyl][l,2,4]lriazol[4,3-a]pyridin; 3-[l,l-difluor-2-(pyridin-3-ylmethoxy)ethyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 2-(2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol [4,3-a]pyridin-3-yl}ethoxy)-N,N-dimethylethanamin; (2,2-difluor-2-{6-|4-(trifluormethoxy)phenylJ[l,2,4Jtriazol|4,3-aJpyridm-3-yl}ethoxy)acetonitril; l,l-difluor-l-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm-3-yl}propan-2-ol; l-cyclopropyl-2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl} ethanol; ethyl (2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}ethoxy)acetat; 3-[l,l-difluor-2-(pyridin-2-ylmethoxy)ethyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 1, l-difluor-2-methyl-1- {6-[4-(trifluormethoxy)phenyl] [ 1,2,4] triazol[4,3-a]pyridin-3-yl }propan-2- ol; 3-(l, l-difluor-2-methoxyethyl)-6-[3-methyl-4-(trifluormethoxy)phenyl] [1,2,4] tri azol[4,3-a]pyridin; 3-{2-[(3,4-difluorbenzyl)oxy]-l,l-difluorethyl}-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-(difluor{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}methyl)pentan-3-ol; 3-(l, l-difluor-2-melhoxyethyl)-6-[2-me thyl-4-(lrifluormelhoxy)phenyl] [1,2,4] lriazol[4,3-a]pyridin; l-(2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm-3-yl}ethoxy)-2- methylpropan-2-ol; 3-(l, l-difluor-2-methoxyethyl)-6-[3-fluor-4-(trifhiormethoxy)phenyl][ 1,2,4] tri azol[4,3-a]pyridin; 3-(l, l-difluor-2-methoxyethyl)-6-(3,5-dilluor-4-phenoxyphenyl)[ 1,2,4] tri azol[4,3-a]pyridin; 3-(2-{[3-(4-chlorphenyl)-l,2-oxazol-5-yl]methoxy}-l,l-difluorethyl)-6-[4- (trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; l-(2-chlorphenoxy)-3-(2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridm-3-yl}ethoxy)propan-2-ol og l-(2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}ethoxy)-3-(2,5-dimethylphenoxy)propan-2-ol og (iii) 7-methyl-6-(4-(trifluormethoxy)phenyl)-3-(trifluormethyl)-[l ,2,4]triazol[4,3-a]pyridin; 6-(3-(trifluormethoxy)phenyl)-3-(trifluormethyl)-[l,2,4]triazol[4,3-a]pyridm; 3-(trifluormethyl)-6-[4-(trifluormethyl)phenyl][l,2,4]triazol[4,3-a]pyridin; 6-(2,4-dichlorphenyl)-3-(trifhiormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(difluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-(3-phenoxyphenyl)-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-chlor-3-(trifluormethyl)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6- (4-chlor-3-fluorphenyl)-3-(trifluormethyl)[ 1,2,4] triazol[4,3-a]pyridin; 7- methyl-6-[3-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridm; 6-(4-tert-butylphenyl)-3-(trifluormethyl)[l,2,4]triazol[4,3-a]p)Tidin; 3-(trifluormethyl)-6-[4-(trimethylsilyl)phenyl][l,2,4]triazol[4,3-a]pyridin; 6-(4-methoxyphenyl)-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(2,2,2-trifluorethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; methyl-4-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin-6-yl] benzoat; 2-{4-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyTidin-6-yl]phenyl}propan-2-ol; 4-[3-(trifluormethyl)[ 1,2,4] triazol[4,3-a]pyridin-6-yl] benzonitril; 6-[2-(lH-tetrazol-5-yl)phenylJ-3-(trifluormethyl)[l,2,4Jtriazol[4,3-a]pyridin; 6-(biphenyl-4-yl)-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-(1-methyl-1H-indazol-5-y1)-3-(trif]uormethyl)[1,2,4]triazo1[4,3-a]pyridin; 6-[4-(lH-l,2,4-triazol-l-yl)phenyl]-3-(ti'ifluormethyl)[l,2,4]tiiazol[4,3-a]pyridin; 6-[4-(4-fluorphenoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridm; 6-[4-(4-chlorphenoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 2-methyl-2-{4-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin-6-yl]phenyl]propannitril; 6-[3-methyl-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(propan-2-ylsulfonyl)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(5-methyl-l,3,4-oxadiazol-2-yl)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[3-(moipholin-4-ylmetliyl)-4-(trifluonnethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-(4-ethoxyphenyl)-3-(trifhiormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-(4-tert-butoxyphenyl)-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6- {3- [ (4-methylpiperazin-1 -yl)methyl] -4-(trifluormethoxy)phenyl} - 3-(trifluonnethyl)-[1,2,4] triazol[4,3-a] pyridin; N,N-dimethyl-l-{2-(trifluormethoxy)-5-[3-(trifluormethyl)[ 1,2,4] triazol[4,3-a]pyridin-6-yl]phenyl}methanamin; 2- ( {2-(trifluormethoxy)-5-[3-(trifluormeth yl)[ 1,2,4] triazol[4,3-a]pyridin-6-yl] benzyl} amino)ethanol; 6-(4-cyclopropylphenyl)-3-(triiluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(pyrazin-2-yloxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(pyridin-3-yloxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6- [4-(cyclopropyloxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 8-methyl-6-[4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridm; 7- methoxy-6-[4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyTidin; 6-[2-methoxy-4-(trifluormethyl)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 3- (trifluormethyl)-6-(3,4,5-trimethoxyphenyl)[l,2,4]triazol[4,3-a]pyridin; 8- (trifluormethoxy)-5-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyTidin-6-yl]quinolin; 6-(3,5-difluor-4-phenoxyphenyl)-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(4-fluor-2-nitrophenoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]p>Tidm; 6-[4-(2-fluorphenoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(pyridin-4-yloxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; N-phcnyW-[3-(trifluormcthyl)[ 1,2,4] triazol[4,3-a]pyridin-6-yl] anilin; N-(2,2,2-trifluorethyl)-4-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin-6-yl]anilin; 6-[4-(phenylsulfanyl)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 4- [3-(trifluormethyl)[l,2,4]triazol[4.3-a]pyridin-6-yl]-N-(2,2,2-trifluor-l-phenylethyl)amlin; 6-[2-bromo-4-(trifluormethoxy)phenylJ-3-(trifluormethyl)[l,2,4Jtriazol[4,3-aJpyridin; 6-[2-(2-methoxypyrimidin-5-yl)-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3- a]pyridin; 6-[2-(pyridin-3-yl)-4-(triiluormethoxy)phenyl]-3-(triiluormethyl)[l,2,4]triazol[4,3-a]pyridin; 2-(trilluormethoxy)-5-[3-(trifluormethyl)[l,2,4Jtriazol|4,3-aJpyridin-6-ylJ anilin; l-{4-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyTidin-6-yl]phenyl}cyclopentanecarbonitril; 6-[2-fluor-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[3-fluor-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]tnazol[4,3-a]pyridin; 6-[4-(cyclopropylmethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[2-methoxy-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[3-(l,3,4-oxadiazol-2-yl)-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3- a]pyridin; l-(4-(3-(trifluormethyl)-[l,2,4]triazol[4,3-a]pyridin-6-yl)phenyl)eth anone; 5- (trifluormethoxy)-8-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin-6-yl]quinolin; 6- [4-(2-methyl-l,3-dioxolan-2-yl)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[3-chlor-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyTidin; (2E)-3-{4-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin-6-yl]phenyl}but-2-ennitril; N-methyl-2-(trifluormethoxy)-5-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin-6-yl]benzamid; 6-[2-(2-methoxyethoxy)-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridm; {5-(trifluormethoxy)-2-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin-6-yl]phenoxy}acetonitril; 6-[3-(3-methyl-l,2,4-oxadiazol-5-yl)-4-(trifluormethoxy)phenyl]-3- (trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[4-(trifhiormethoxy)-3-(trifluormethyl)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridm; l-(4-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyTidin-6-yl]phenyl}cyclopropancarbonitril; 6-[2,4-bis(trifluormethyl)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 5- methyl-6-[4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6- [4-(2-methoxypropan-2-yl)phenyl]-3-(trifluormeth yl)[ 1,2,4] tri azol[4,3-a]pyri din; 6-[2-ethoxy-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-[2-(propan-2-yloxy)-4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 4- {4-[3-(trifluormcthyl)[l,2,4]triazol[4,3-a]pyridin-6-yl]phcnyl}tctrahydro-2H-pyran-4-carbomtril; 6-{4-[difluor(pyridin-3-yl)methoxy]phenyl}-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin; 6-{4-[difluor(phenyl)methoxy]phenyl}-3-(triiluormethyl)[l,2,4]triazol[4,3-a]pyridin; 5- chlor-2-( {4-[3-(trilluormethyl)[ 1,2,4] tri azol[4,3-a]pyridin-6-yl] phenyl }amino)benzonitril; 5-(methoxymethyl)-6-[4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridm; N-methyl-N-phenyl-4-[3-(trifluormethyl)[ 1,2,4] tri azol[4,3-a]pyridin-6-yl] anilin; ({6-[4-(trifluormethoxy)phenyl]-3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin-5-yl} methoxy) acetonitril; 4-(difluor{4-[3-(trifluormethyl)[l,2,4]triazol[4,3-a]pyridin-6-yl]phenoxy}methyl)benzonitril; 4-chlor-N-{4-[3-(trifluormeth yl)[ 1,2,4] triazol[4,3-a] pyri din-6-yl]phenylJ anilin; 4-fluor-N-{4-[3-(trifluormethyl)[ 1,2,4]triazol[4,3-a]pyridin-6-yl]phenyl {anilin; 6-[4-(pentafluor-lambda~6—sulfanyl)phenyl]-3-(trifluormethyl)[ 1,2,4]triazol[4,3-a]pyridin og 6-(2-chlor-4-nitrophenyl)-3-(trifluormethyl)ll,2,4Jtriazol[4,3-aJpyridin.
  8. 8. Forbindelse ifølge krav 1, hvor R1 er aryl eventuelt substitueret med halo, hydroxyl, methoxy, ethoxy, -OCF3 eller amino.
  9. 9. Forbindelse ifølge krav 8 udvalgt fra gruppen bestående af: {6-|4-(trifluormethoxy)phenylJ[l,2,4J tri azol|4,3-aJpyridin-3-yl} eddikesyre; 3-(difluormethyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(propan-2-yl)-6-[4-(trifluormethoxy)phenyl] [ 1,2,4]triaz,ol[4,3-a]pyridin; methyl 6-[4-(trifhiormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-carboxylat; N-methyl-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-carboxamid; 3-methyl-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-8-amin; 3-methyl-6-[2-methyl-4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-8-amin; N-{3-methyl-6-[2-methyl-4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-8-yl}acetamid; 3-(l-methyl-lH-pyrazol-4-yl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; N-{3-methyl-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-8-yl}propanamid; N-({6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}methyl)methansulfonamid; 3-(difluormethyl)-8-methoxy-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[(benzyloxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[(cyclopropylmethoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[(2,2,2-trifluorethoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; {6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}methanol; 3-phenoxy-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 2,2,2-trifluor-l-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}ethanol; 3-(2-chlor-l,l-difluorethyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; N,N-dimethyl-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-amin; 3-(phenylsulfanyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(cyclopropylethynyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 2-methyl-4-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}but-3-yn-2-ol; N-(2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl} ethyl)methansulfonamid; N-(2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}ethyl)pyridin-2- carboxamid; 3-methoxy-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-(2,2,2-trifluorethoxy)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 6-[4-(trifluormethoxy)phenyl]-3-({[4-(trifluormethyl)benzyl]oxy}methyl)[l,2,4]triazol[4,3- a]pyridin; 3-{ [(4-fluorbenzyl)oxy] methyl }-6-[4-(trifluormethoxy)phenyl] [ 1,2,4] tria7,ol[4,3-a]pyridin; 3-{[(2-iluorbenzyl)oxy]melhyl}-6-[4-(triiluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 6-[4-(trifluormethoxy)phenyl]-3-({[2-(trifluormethyl)benzyl]oxy}methyl)[l,2,4]triazolo4,3- a]pyridin; 3-{ [(2,4-difluorbenzyl)oxy]methyl }-6-[4-(trifluormethoxy)phenyl] [1,2,4]triazol[4,3-a]pyridin; 3-{[(4-chlorbenzyl)oxy]melhyl]-6-[4-(lritluormeLhoxy)phenyl][l,2,4]lriazol[4,3-a]pyridin; 3-({[4-(trifluormethoxy)benzyl]oxy (methyl)-6-[4-(trifluormethoxy)phenyl] [1,2,4] triazol[4,3-a]pyridin; N-(2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}ethyl)benzamid; 3-[(pyridin-2-ylmethoxy)melhyl]-6-[4-(lriiluormelhoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-[(l-phenylethoxy)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{ l-[difhior(pyridin-3-yl)methoxy]ethyl}-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{[(2,4-dichlorbenzyl)oxy]methyl}-6-[4-(trifluormethoxy)phenyl][l,2,4]lriazol[4,3-a]pyridin; 3-{[(2,4-dimethylbenzyl)oxy]methyl}-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{[(5-methylpyridin-2-yl)methoxy]methyl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3- a]pyridin; 3-[l-(pyridin-2-ylmethoxy)ethyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin; 3-{ [difluor(pyridin-3-yl)methoxy] methyl }-6-[4-(trifluormethoxy)phenyl] [1,2,4] triazol[4,3-a]pyridin; 6-[4-(tnfluormethoxy)phenyl]-3-[3-(trifluormethyl)phenoxy][l,2,4]triazol[4,3-a]pyridin; 3-(4,4-difluarpiperidm-l-yl)-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyTidin; l-(2,2-difluor-2-{6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-yl}ethyl)-3- phenylurea; 6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin-3-carboxamid; 3-(2-methylphenoxy)-6-[4-(trifhiormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin og 3-[chlor(difluor)methyl]-6-[4-(trifluormethoxy)phenyl][l,2,4]triazol[4,3-a]pyridin.
  10. 10. Forbindelse ifølge krav 1, der er 6-(4-(trifluormethoxy)phenyl)-3-(trifluormethyl)-[l,2,4]triazol[4,3-a]pyridin, repræsenteret ved strukturen
    eller et farmaceutisk acceptabelt salt deraf.
  11. 11. Forbindelse ifølge et hvilket som helst af kravene 1 til 10 til anvendelse i en fremgangsmåde til behandling af en sygdomstilstand hos et pattedyr, der kan Undres ved behandling med et middel, der er i stand til at reducere sen natriumstrøm.
  12. 12. Anvendelse af en forbindelse ifølge et hvilket som helst af kravene 1 til 10 til fremstilling af en farmaceutisk sammensætning til behandling af en sygdomstilstand hos et pattedyr, der kan lindres ved behandling med et middel, der er i stand til at reducere sen natriumstrøm.
  13. 13. Forbindelse ifølge krav 11 eller anvendelse ifølge krav 12, hvor sygdomstilstanden er en kardiovaskulær sygdom, der er udvalgt fra en eller flere af atrial og vcntrikulær arrhythmi, hjertesvigt (indbefattende kongestivt hjertesvigt, diastolisk hjertesvigt, systolisk hjertesvigt, akut hjertesvigt), Prinzmetals (variant) angina, stabil og ustabil unstable angina, motionsinduceret angina, kongestiv hjertesygdom, iskæmi, tilbagevendende iskæmi, reperfusionsskade, myokardieinfarktion, akut coronarsyndrom, perifer arteriesygdom, pulmonal hypertension og claudicatio intermittens; eller sygdomstilstanden er diabetes eller diabetisk perifer neuropath eller sygdomstilstanden resulterer i én eller flere af neuropatisk smerte, epilepsi, anfald eller paralyse.
  14. 14. Farmaceutisk sammensætning, der omfatter en farmaceutisk acceptabel excipiens og en terapeutisk effektiv mængde af forbindelsen ifølge et hvilket som helst af kravene 1 til 10 eller et farmaceutisk acceptabelt salt, en farmaceutisk acceptabel ester eller et farmaceutisk acceptabelt hydrat deraf.
DK10737724.4T 2009-07-27 2010-07-26 Kondenserede, heterocykliske forbindelser som jernkanalmodulatorer DK2464645T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22886409P 2009-07-27 2009-07-27
US36003710P 2010-06-30 2010-06-30
PCT/US2010/043264 WO2011014462A1 (en) 2009-07-27 2010-07-26 Fused heterocyclic compounds as ion channel modulators

Publications (1)

Publication Number Publication Date
DK2464645T3 true DK2464645T3 (da) 2017-10-23

Family

ID=42751632

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10737724.4T DK2464645T3 (da) 2009-07-27 2010-07-26 Kondenserede, heterocykliske forbindelser som jernkanalmodulatorer

Country Status (22)

Country Link
US (2) US8952034B2 (da)
EP (1) EP2464645B1 (da)
CN (1) CN102725290B (da)
AR (1) AR077598A1 (da)
AU (1) AU2010276537B2 (da)
CA (1) CA2774715C (da)
CY (1) CY1119584T1 (da)
DK (1) DK2464645T3 (da)
EA (1) EA025824B1 (da)
ES (1) ES2642586T3 (da)
HR (1) HRP20171454T8 (da)
HU (1) HUE034911T2 (da)
LT (1) LT2464645T (da)
ME (1) ME02847B (da)
NZ (1) NZ598942A (da)
PL (1) PL2464645T3 (da)
PT (1) PT2464645T (da)
RS (1) RS56410B1 (da)
SI (1) SI2464645T1 (da)
TW (2) TWI542587B (da)
UY (1) UY32805A (da)
WO (1) WO2011014462A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010276537B2 (en) 2009-07-27 2015-04-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
MX2012015096A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Compuestos heterociclicos fusionados como moduladores del canal ion.
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
EP2707361B1 (en) 2011-05-10 2017-08-23 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (da) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
AU2012312266A1 (en) * 2011-09-21 2013-05-02 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
JP6042438B2 (ja) 2011-09-27 2016-12-14 ジェンフィットＧｅｎｆｉｔ Ｒｅｖ−ｅｒｂアゴニストとしての６−置換トリアゾロピリダジン類の誘導体
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
KR20140091022A (ko) 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EA026393B1 (ru) 2012-05-22 2017-04-28 Дженентек, Инк. N-замещенные бензамиды и их применение в лечении боли
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
BR112015022488A2 (pt) * 2013-03-14 2017-07-18 Genentech Inc triazolopiridinas substituídas e métodos de uso das mesmas
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EA201691085A1 (ru) 2013-11-27 2017-02-28 Дженентек, Инк. Замещенные бензамиды и способы их применения
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR101871613B1 (ko) * 2013-12-20 2018-06-26 길리애드 사이언시즈, 인코포레이티드 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
KR102461134B1 (ko) 2014-01-21 2022-10-28 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
CA2881544A1 (en) * 2014-02-13 2015-08-13 Anna Chiu Solid forms of a late sodium current inhibitor
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
CA2986045A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
CN108137477A (zh) 2015-08-27 2018-06-08 基因泰克公司 治疗化合物及其使用方法
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
MA43304A (fr) 2015-11-25 2018-10-03 Genentech Inc Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
KR20190078587A (ko) 2016-10-17 2019-07-04 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN116763791A (zh) * 2016-11-28 2023-09-19 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
CN111936494A (zh) 2018-03-30 2020-11-13 豪夫迈·罗氏有限公司 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪
CN117756800A (zh) 2018-05-30 2024-03-26 普拉克西斯精密药物股份有限公司 离子通道调节剂
EA202092908A1 (ru) * 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
BR112022010186A2 (pt) * 2019-11-26 2022-08-09 Praxis Prec Medicines Inc Moduladores de canal iônico
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
JP2023507610A (ja) * 2019-12-19 2023-02-24 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｃｄ２０６モジュレーター、その使用、および調製方法
WO2023211852A1 (en) * 2022-04-26 2023-11-02 Praxis Precision Medicines, Inc. Treatment of neurological disorders

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL128591C (da) * 1965-07-02
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4230705A (en) * 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4244953A (en) 1979-10-24 1981-01-13 American Cyanamid Company Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4812565A (en) 1982-09-30 1989-03-14 A. H. Robins Company, Incorporated Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4746655A (en) 1987-06-10 1988-05-24 A. H. Robins Company, Incorporated Fused aromatic-spiropiperidine oxazepinones(and thiones)
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE4010488A1 (de) 1990-03-31 1991-10-02 Hoechst Ag Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten
CA2044564A1 (en) * 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
CN1060467A (zh) 1990-09-25 1992-04-22 武田药品工业株式会社 1，3-苯并嗪衍生物、其生产方法和用途
JPH04209692A (ja) 1990-12-03 1992-07-31 Asahi Glass Co Ltd フォトクロミック材料
EP0522606B1 (en) 1991-05-10 1996-04-03 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
US5939412A (en) 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ZA924760B (en) 1991-06-28 1993-03-31 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5663166A (en) 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH06107647A (ja) 1992-08-12 1994-04-19 Takeda Chem Ind Ltd １，３−ベンゾオキサジン誘導体の製造法
US5442055A (en) 1992-11-13 1995-08-15 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US6011150A (en) 1992-11-13 2000-01-04 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
GB9225860D0 (en) 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9226302D0 (en) 1992-12-17 1993-02-10 Smithkline Beecham Plc Pharmaceuticals
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
DE19526173A1 (de) 1995-07-18 1997-01-30 Hoechst Ag Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung
JPH09157262A (ja) 1995-12-08 1997-06-17 Tanabe Seiyaku Co Ltd アゼチジノン誘導体及びその合成中間体の製法
GB9619492D0 (en) 1996-09-18 1996-10-30 Smithkline Beecham Plc Novel treatment
US6159979A (en) 1997-04-18 2000-12-12 Smithkline Beecham P.L.C. Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
JP3964053B2 (ja) 1997-07-10 2007-08-22 三井化学株式会社 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法
AU9257998A (en) 1997-09-08 1999-03-29 Unilever N.V. Method for enhancing the activity of an enzyme
EA002755B1 (ru) * 1998-01-21 2002-08-29 Мерк Шарп Энд Домэ Лимитед Производные триазолопиридазина в качестве лигандов для гамк рецепторов
CA2319173A1 (en) 1998-02-11 1999-08-19 Jingwu Duan Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
CA2320354A1 (en) 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
EP1087968A1 (en) * 1998-06-16 2001-04-04 MERCK SHARP & DOHME LTD. Triazolo-pyridine derivatives as ligands for gaba receptors
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CA2373073A1 (en) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
CZ2002720A3 (cs) 1999-08-27 2002-09-11 The Procter & Gamble Company Složky zesilující bělení, prostředky a způsoby praní s využitím složek zesilujících bělení
AU7072100A (en) 1999-08-27 2001-03-26 Procter & Gamble Company, The Stable formulation components, compositions and laundry methods employing same
CN1382207A (zh) 1999-08-27 2002-11-27 宝洁公司 利用阳离子配制组分的颜色保护性洗衣方法
BR0013608A (pt) 1999-08-27 2002-05-21 Procter & Gamble Disponibilidade controlada de componentes de formulações, composições e métodos para lavar roupa empregando os mesmos
MXPA02002129A (es) 1999-08-27 2002-09-18 Procter & Gamble Componentes de formulacion de accion rapida, composiciones y metodos para lavanderia que los emplean.
AU6935700A (en) 1999-08-27 2001-03-26 Procter & Gamble Company, The Color safe laundry methods employing zwitterionic formulation components
AU6935500A (en) 1999-08-27 2001-03-26 Procter & Gamble Company, The Stability enhancing formulation components, compositions and laundry methods employing same
US6469020B2 (en) 2000-05-15 2002-10-22 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives
MXPA03000952A (es) 2000-08-01 2003-09-05 Ono Pharmaceutical Co Compuestos derivados de 3,4-dihidroisoquinolina y medicamentos que los contienen, como el ingrediente activo.
CA2419255A1 (en) 2000-08-29 2002-03-07 Ish Kumar Khanna Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
EP1695716A2 (en) 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
PL363959A1 (en) 2001-03-09 2004-11-29 Pfizer Products Inc. Triazolopyridines as anti-inflammatory agents
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2005089298A (ja) 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2003277384A (ja) 2002-03-26 2003-10-02 Kyorin Pharmaceut Co Ltd 縮合ニ環式ピリジン誘導体
JP2003321461A (ja) 2002-04-25 2003-11-11 Kyorin Pharmaceut Co Ltd 縮合ビフェニル誘導体
AU2003253150A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
PA8579601A1 (es) * 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
WO2004026292A1 (ja) 2002-09-20 2004-04-01 Tsumura & Co. 鎮咳薬
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
AU2003285946A1 (en) 2002-10-22 2004-05-13 The Trustees Of The University Of Pennsylvania Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
WO2004043940A1 (en) 2002-11-07 2004-05-27 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004062616A2 (en) 2003-01-13 2004-07-29 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE10317526A1 (de) 2003-04-16 2004-11-04 Degussa Ag Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen
CN100384856C (zh) 2003-04-17 2008-04-30 麦克公司 趋化因子受体活性调节剂杂环基环戊基四氢异喹啉和杂环基环戊基四氢吡啶并吡啶
JP2006524641A (ja) * 2003-04-25 2006-11-02 ハー・ルンドベック・アクチエゼルスカベット 置換されたインドリンおよびインドール誘導体
US20060148805A1 (en) * 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
AU2004263515A1 (en) * 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
EP1708709A1 (en) 2003-12-18 2006-10-11 Pfizer Products Incorporated METHODS OF TREATING ACUTE INFLAMMATION IN ANIMALS WITH p38 MAP KINASE INHIBITORS
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
WO2006002470A1 (en) 2004-06-30 2006-01-12 Monash University Chiral ligands for asymmetric catalysis
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
US7572783B2 (en) 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
EP1784188B1 (en) 2004-08-23 2010-07-14 Merck Sharp & Dohme Corp. Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2005285083B2 (en) 2004-09-13 2011-03-10 Merck Sharp & Dohme Corp. Tricyclic anilide spirohydantoin CGRP receptor antagonists
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
US7579348B2 (en) * 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
SI2444079T1 (sl) 2005-05-17 2017-05-31 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje očesnih motenj
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
JP2008543867A (ja) 2005-06-17 2008-12-04 ワイス セロトニン阻害剤ならびに５−ｈｔ１ａアゴニストおよびアンタゴニストとして有用な三環系化合物
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
WO2007004028A2 (en) 2005-06-30 2007-01-11 Ranbaxy Laboratories Limited Processes for the preparation of penems and its intermediate
GB0516963D0 (en) * 2005-08-18 2005-09-28 Carbonite Corp Liquid dispensers
WO2007023750A1 (ja) 2005-08-26 2007-03-01 National University Corporation University Of Toyama 乾燥羊膜及び羊膜の乾燥処理方法
JP2009508963A (ja) 2005-09-21 2009-03-05 インサイト・コーポレイション アミド化合物および医薬組成物としてのその使用
MX2008004024A (es) 2005-09-23 2009-02-27 Schering Corp Antagonistas de receptor de glutamato metabotropico-1 tetraciclicos fusionados como agentes terapeuticos.
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
WO2007061696A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam bicyclic cgrp receptor antagonists
CA2629409A1 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam aryl cgrp receptor antagonists
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
CN101330914A (zh) * 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
US8013073B2 (en) 2005-12-30 2011-09-06 Chevron Oronite Company Llc Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds
RU2008143179A (ru) * 2006-03-31 2010-05-10 Новартис АГ (CH) Органические соединения
AU2007258313A1 (en) 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
WO2008005338A1 (en) 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
ES2431466T3 (es) 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
WO2008007661A1 (fr) 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Composé hétérocyclique tricycique et son utilisation
US20100035756A1 (en) * 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
WO2008063287A2 (en) * 2006-10-06 2008-05-29 Abbott Laboratories Novel imidazothiazoles and imidazoxazoles
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
CN101573333B (zh) 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
EP2128134A1 (en) 2006-11-02 2009-12-02 Shionogi&Co., Ltd. Sulfonylurea derivative capable of selectively inhibiting mmp-13
US20080153840A1 (en) 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
US20100144715A1 (en) 2007-02-28 2010-06-10 Hoyt Scott B Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
WO2009026444A1 (en) 2007-08-22 2009-02-26 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
MX2010002760A (es) 2007-09-12 2010-04-01 Wyeth Llc Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
NZ585306A (en) 2007-12-19 2012-05-25 Genentech Inc 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
WO2009089027A1 (en) * 2008-01-09 2009-07-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health Phosphodiesterase inhibitors
BRPI0908428A2 (pt) 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
WO2009137462A2 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2009137499A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase
DE102008024182A1 (de) 2008-05-19 2009-11-26 Merck Patent Gmbh Verbindungen für organische elektronische Vorrichtung
CA2726508C (en) 2008-06-17 2016-06-07 Astrazeneca Ab Pyridine compounds
WO2010006292A1 (en) 2008-07-11 2010-01-14 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
WO2010018686A1 (ja) 2008-08-12 2010-02-18 日本曹達株式会社 含窒素ヘテロ環誘導体および農園芸用殺菌剤
EP2323974A1 (en) 2008-08-18 2011-05-25 Ube Industries, Ltd. Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto
US20100056536A1 (en) 2008-09-04 2010-03-04 Charles Antzelevitch Method of treating atrial fibrillation
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
US8389500B2 (en) 2008-10-30 2013-03-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2010077686A1 (en) 2008-12-08 2010-07-08 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
WO2010077680A2 (en) 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 ｃ형 간염 억제제
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
AU2010276537B2 (en) 2009-07-27 2015-04-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2011036280A1 (en) 2009-09-28 2011-03-31 F. Hoffmann-La Roche Ag Benzoxazepin pi3k inhibitor compounds and methods of use
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
MX2012015096A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Compuestos heterociclicos fusionados como moduladores del canal ion.
WO2012019071A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating sarcopenia
WO2012019076A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
WO2012037105A1 (en) 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
EP2643316A2 (en) 2010-11-24 2013-10-02 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
EP2707361B1 (en) 2011-05-10 2017-08-23 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (da) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers

Also Published As

Publication number Publication date
NZ598942A (en) 2014-02-28
TWI542587B (zh) 2016-07-21
SI2464645T1 (sl) 2017-10-30
AU2010276537A1 (en) 2012-05-24
HRP20171454T8 (hr) 2018-01-12
EP2464645B1 (en) 2017-07-05
ES2642586T3 (es) 2017-11-16
PT2464645T (pt) 2017-10-11
US20140303158A1 (en) 2014-10-09
PL2464645T3 (pl) 2017-12-29
EA201290121A1 (ru) 2012-10-30
CN102725290A (zh) 2012-10-10
CN102725290B (zh) 2016-03-09
US20110021521A1 (en) 2011-01-27
TW201116528A (en) 2011-05-16
AR077598A1 (es) 2011-09-07
US8952034B2 (en) 2015-02-10
HUE034911T2 (hu) 2018-03-28
WO2011014462A1 (en) 2011-02-03
CY1119584T1 (el) 2018-03-07
EA025824B1 (ru) 2017-02-28
EP2464645A1 (en) 2012-06-20
UY32805A (es) 2011-02-28
AU2010276537B2 (en) 2015-04-16
RS56410B1 (sr) 2018-01-31
ME02847B (me) 2018-01-20
TW201542545A (zh) 2015-11-16
HRP20171454T1 (hr) 2017-12-01
LT2464645T (lt) 2017-10-25
US9371329B2 (en) 2016-06-21
CA2774715A1 (en) 2011-02-03
CA2774715C (en) 2018-04-03
TWI490217B (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
DK2464645T3 (da) Kondenserede, heterocykliske forbindelser som jernkanalmodulatorer
EP2588197B1 (en) Fused heterocyclic compounds as ion channel modulators
AU2012279214B2 (en) Oxazepines as ion channel modulators
AU2015224425B2 (en) Fused benzoxazepinones as ion channel modulators
OA20251A (en) Fused benzoxazepinones as ion channel modulators
NZ618684B2 (en) Oxazepines as ion channel modulators